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INTRODUCTION 
 
Systemic lupus erythematosus (SLE) is the prototype of systemic 
autoimmune diseases. It affects predominantly women in their reproductive 
years. Remissions and relapses characterize the disease. The clinical 
manifestations and their severity in individual patients may vary considerably 
and, therefore, the treatment strategy needs to be tailored accordingly.1,2,3,4. 
Systemic lupus erythematosus (SLE) has frequent and potentially serious 
neuropsychiatric (NP) manifestations that are of importance in the management 
of the disease. Lack of a diagnostic gold standard and ambiguous terminology 
have hampered epidemiologic research in neuropsychiatric systemic lupus 
erythematosus (NPSLE). The reported prevalence of NPSLE varies widely, 
from 14% to 75%, because of inconsistent classifications and selected patient 
populations in tertiary referral centers. A nomenclature system recently 
developed by the American College of Rheumatology (ACR) is the first step 
toward standardized and internationally accepted classification of 
NPSLE.1,4,5,6,7. This nomenclature comprises case definitions including 
diagnostic criteria, exclusions, and methods of ascertainment for a total of 19 
syndromes.50 The purpose of this cross-sectional, hospital based study is to 
assess the validity of the ACR nomenclature and case definitions for NPSLE. 
 AIMS AND OBJECTIVES 
 
 
1. To study the Prevalence of Neuropsychiatric manifestations among SLE 
patients admitted in Government General Hospital, Chennai. 
2. To categorize and study the prevalence of the different Neuropsychyatric 
syndromes described  by American College of Rheumatologists’ 
nomenclature. 
3. To study the prevalence of Peripeheral Nerve disorders among these 
patients by electrophysiology. 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Systemic lupus erythematosus (SLE) is a chronic, multifaceted 
inflammatory disease that can affect every organ system of the body. SLE is 
protean in its manifestations and follows a relapsing and remitting course.1,2 
Pathophysiology 
SLE is an autoimmune disorder characterized by multisystem 
microvascular inflammation with the generation of autoantibodies. Although 
the specific cause of SLE is unknown, multiple factors are associated with the 
development of the disease, including genetic, racial, hormonal, and 
environmental factors.  Many immune disturbances, both innate and acquired, 
occur in SLE.9,10 
     
 In systemic lupus erythematosus (SLE), many genetic-susceptibility factors, environmental triggers, antigen-antibody responses, B-cell and T-cell interactions, 
and immune clearance processes interact to generate and perpetuate autoimmunity 
One proposed mechanism for the development of autoantibodies involves 
a defect in apoptosis that causes increased cell death and a disturbance in 
immune tolerance. The redistribution of cellular antigens during apoptosis leads 
to a cell-surface display of plasma and nuclear antigens in the form of 
nucleosomes. Thus, dysregulated (intolerant) lymphocytes begin targeting 
normally protected intracellular antigens.9 
Immune complexes form in the microvasculature, leading to complement 
activation and inflammation. Moreover, antibody-antigen complexes deposit on 
the basement membranes of skin and kidneys. In active SLE, this process has 
been confirmed based on the presence of complexes of nuclear antigens such as 
DNA, immunoglobulins, and complement proteins at these sites. Serum 
antinuclear antibodies (ANAs) are found in virtually all individuals with active 
SLE, and antibodies to native double-stranded DNA (dsDNA) are relatively 
specific for the diagnosis of SLE. 
Frequency –  International:  
Worldwide, the prevalence of SLE varies. Although the prevalence of 
SLE is high in black persons in the United Kingdom, the disease is rarely 
reported among blacks who live in Africa. According to a recent report from the 
National Arthritis Data Working Group, approximately 250,000 Americans 
have systemic lupus.4,6,7 
India: SLE is rare in India. A prevalence study in India (carried out in a rural 
population near Delhi) found a point prevalence of 3 per 100,000. This is a 
much lower figure than reported from the west (varying from 12.5 per 100,000 
adults in England to 39 per 100,000 in Finland  and 124 per 100,000 in USA). 
However, a fair number of cases of SLE are encountered in any large hospital in 
India. The incidence of SLE has tripled in the past 40 years, mainly as a result 
of improved diagnosis of mild disease.5 
Mortality/Morbidity 
The natural history of SLE varies from relatively benign disease to 
rapidly progressive and even fatal disease. SLE often waxes and wanes in 
affected individuals throughout life, and features of the disease vary greatly 
between individuals. The disease course is milder and survival rate higher 
among persons with isolated skin and musculoskeletal involvement than in 
those with renal and CNS disease.4 
SLE carries an average 10-year survival rate that now exceeds 90%. Prior 
to 1955, the 5-year survival rate was less than 50%. Decreased mortality rates 
associated with SLE can be attributed to earlier diagnosis (including milder 
cases), improvement in disease-specific treatments, and advances in general 
medical care. According to the CDC, one third of SLE-related deaths in the 
United States occur in patients younger than 45 years, making this a serious 
issue despite declining overall mortality rates. In 1976, Urowitz first reported 
bimodal mortality in early versus late SLE, noting that SLE-related deaths 
usually occur within the first 5-10 years of symptom onset.12 
Infectious complications related to active SLE and immunosuppressive 
treatment are now the most common cause of death in early active SLE, and 
accelerated arteriosclerosis is a key cause of late mortality. The Framingham 
Offspring Study demonstrated that women aged 35-44 years with SLE were 50 
times more likely to develop myocardial ischemia than healthy women. 11,12 
Sex: SLE frequently starts in women of childbearing age, and the use of 
exogenous hormones has been associated with lupus onset and flares, 
suggesting a role for hormonal factors in the pathogenesis of the disease. The 
risk of SLE development in men is similar to that in prepubertal or 
postmenopausal women.4  
Age: A correlation between age and incidence of SLE mirrors peak years of 
female sex hormone production. The prevalence of SLE is highest among 
women aged 14-64 years. SLE does not have an age predilection in males.4 
 
 
Diagnosis of SLE 
 
The American College of Rheumatology has a criteria for the 
classification of patients as having SLE. If a patient has, at any time in his or 
her medical history, 4 of the 11 criteria documented (Table below), the 
diagnosis of SLE can be made with about 95% specificity and 85% 
sensitivity.5,13 
Revised ACR classification criteria for SLE (1997 update) 13 
 
Serology in SLE 
 
Since SLE is associated with a number of autoantibodies, it is important 
to understand their relevance in clinical practice. Some of these are useful as 
diagnostic markers, others help in quantifying disease activity and still others 
are primarily of research interest, making no contribution to patient care. A 
brief discussion follows: 
Antinuclear antibody (ANA): 
ANA is a good screening test for SLE because 95% of cases show a high 
titre (1:80 or more) of this autoantibody. A negative test result makes the 
diagnosis highly improbable. ANA may be positive in other rheumatic disorders 
such as systemic sclerosis, Sjogren’s syndrome, overlap syndrome, 
antiphospholipid syndrome, polymyositis and rheumatoid arthritis. Like the 
rheumatoid factor test, ANA may also be positive in chronic infections, 
malignancies and in normal individuals. Thus, the specificity of ANA for 
diagnosis of SLE is quite low (app. 40% only). Performing serial titres of ANA 
in a diagnosed case of SLE is of no clinical value because it does not correlate 
well with disease activity.5,15 
ANAs are actually a family of autoantibodies, which may be directed 
against any one of the following nuclear antigens: 1. Double stranded-DNA, 2. 
Extractable nuclear antigens (ENA), 3. Histones, 4. Nuclear RNA.5 
Anti-double stranded DNA antibody (anti-dsDNA):  
This test has high specificity for SLE. The positivity of anti-dsDNA in 
SLE at the time of presentation is in the range of 60% (although the cumulative 
positivity during the course of disease may approach 90%). Hence, anti-ds 
DNA can not be a good screening test for SLE. When positive, the test 
establishes the diagnosis of SLE. The anti-dsDNA titres most often correlate 
with disease activity.17 
The classic finding of a low C-reactive protein (CRP) level but an 
elevated erythrocyte sedimentation rate (ESR) or plasma viscosity was seen in 
about 40% of patients. In previously undiagnosed patients thought to have SLE, 
the principal diagnostic study is the antinuclear antibody (ANA) test. 
Although many rheumatologists consider this test to be 100% sensitive 
for diagnosis, a positive ANA result alone is not sufficient for diagnosis. 
Positive test results are seen in other autoimmune conditions and in a certain 
percentage of the general population (especially the elderly). Anti-DNA 
antibody testing is positive in only about 70% of CNS episodes. 
When a positive ANA result is thought to be clinically relevant, follow 
up with an antibody to native, double-stranded DNA (dsDNA antibody) to 
confirm the diagnosis of SLE. An autoantibody panel should be checked for 
related pathogenic antibodies.5,20 
Of particular interest are the serum antiribosomal P antibody (which is 
positive in 60% of cases of lupus psychosis) and the family of antibodies known 
collectively as antiphospholipid antibodies (including the anticardiolipin 
antibody, [ACLA]). These may be positive in hypercoagulable states, 
myelopathy, and LSE. APA were present in 16-60% of the reported cases. 
Complement studies (C3, C4, CH50) may be useful to determine disease 
activity in patients known or thought to have SLE. 
Antiphospholipid syndrome was first described in association with SLE 
but also may occur independently. This should be searched for in patients with 
known to have SLE with neurologic complications, especially myelopathy or 
cerebrovascular events, whether embolic, thrombotic, or hemorrhagic. 
Concomitant SLE and antiphospholipid syndrome has been shown to increase 
the risk of nervous system involvement. 
In addition to testing serum ACLA, hematologic studies may reveal a 
circulating anticoagulant (originally called the lupus anticoagulant). 
Prolongation of the activated partial thromboplastin time (aPTT) only identifies 
30% of circulating anticoagulants. Sensitivity may be enhanced by the Russell 
viper venom test, the kaolin clotting time, or variations using hexagonal phase 
phospholipids or other adsorbents. 
CSF abnormalities were seen in 30-40% of patients reported. The 
frequency of CSF oligoclonal bands has varied between reports, lower range 
generally around 20%. An abnormal CSF is generally associated with a poor 
prognosis. Cerebrospinal fluid (CSF) examination is most useful to exclude 
infection, especially in immunocompromised patients. However, CSF can 
reflect increased CNS lupus activity by showing elevated levels of white cells, 
protein, immunoglobulin synthesis, or absolute immunoglobulin G (IgG). 
Antineuronal nuclear antibodies (ANNA) have some value in confirming CNS 
disease when performed on CSF but are less specific or sensitive than a serum 
test.4,5 
Conventional blood studies have varying utility in diagnosing SLE, 
depending on associated conditions and manifestations. 
Electrolytes, glucose, and calcium are especially worth checking in the 
setting of new-onset generalized seizures or acute encephalopathy. Acid-based 
disturbances may be obvious on review of electrolytes, but an arterial blood gas 
analysis may be useful to assess or follow such a disturbance, especially in the 
obtunded, acutely ill patient. 
Lupus nephritis activity is customarily followed by assessing casts in the 
urine and proteinuria measured by dipstick or 24-hour collection but may be 
followed more roughly by the BUN and creatinine levels. Acute increases in 
BUN may produce metabolic encephalopathy, but on a chronic basis, very high 
BUN elevations may be surprisingly well tolerated. 
The CBC in SLE may demonstrate a hemolytic anemia with 
reticulocytosis or reductions of neutrophils, lymphocytes, or platelets. 
Muscle enzyme levels (creatine kinase, aldolase) may be moderately or 
severely elevated with lupus myopathy, although normal levels also may be 
seen with clinical or biopsy-proven disease. Normal creatine kinase levels, 
therefore, do not reliably distinguish between SLE myositis and drug-related 
(steroid, hydroxychloroquine) myopathy.24 
Imaging Studies 
Joseph et al (2007) in their study have reported that 35% of CT brain 
scans were abnormal and 65% of MR scans, but CT remains valuable in 
identifying hemorrhages and larger infarcts.  Neuroradiologic evaluation favors 
MRI over CT scans because subtle ischemia or cerebritis may be seen with 
greater sensitivity. The most common findings with either study are ischemic 
zones that may correspond to cortical or subcortical infarcts and may be large or 
small according to the size of vessel involved and the mechanism of stroke. See 
the image below for an example of ischemia visible on MRI.27 
Other vague areas of patchy cortical or subcortical abnormality (lucency 
on CT, T2 signal intensity on MRI) may correspond to small vessel vasculitis or 
cerebritis, but distinction from opportunistic infection (eg, toxoplasmosis, 
progressive multifocal leukoencephalopathy) often cannot be made on 
radiographic grounds, requiring other studies, including cerebral biopsy. With 
either CT or MRI, contrast enhancement increases the sensitivity for acute and 
subacute cerebral lesions.28 
A frequent clinical problem occurs when the MRI reveals multiple small 
T2 signal intensities in the white matter, making it difficult to distinguish 
between multiple sclerosis and SLE or other vasculitides. Although many 
clinical and laboratory factors assist in this differential diagnosis, the MRI 
appearance is more supportive of SLE when the lesions are not confined to 
periventricular white matter but favor the gray-white junction or even involve 
gray matter of cortex or deep nuclei when the lesions are rounded or patchy in 
shape. If the lesions are radially oriented along white matter tracts, favor the 
periventricular white matter, and involve the corpus callosum, then multiple 
sclerosis is a more likely diagnosis.27,28,29 
Perisulcal cortical atrophy is reported as a frequent finding on CT. 
CT scanning may detect calcifications in patients with long-standing 
cerebritis. 
Dural sinus thrombosis is a rare complication of SLE-associated 
hypercoagulability and is often seen in association with antiphospholipid 
antibodies. Radiologically, flow defects in one or more venous sinuses may be 
imaged on MRI, MR venous angiography, conventional angiography, or 
radionuclide brain scan. Associated edema or hemorrhagic infarcts may be 
obvious on MRI or CT scans. 
PET scanning and magnetic resonance spectroscopy (MRS) promise 
greater sensitivity for cerebritis. However, the greatest utility of imaging studies 
remains the exclusion of unexpected mass lesions or opportunistic infectious 
processes. 
When embolic stroke occurs in patients with proven or suspected SLE, 
echocardiography is mandatory to assess for valvular and other intracardiac 
lesions. In the patient known to have SLE who presents with an apparently 
nonembolic stroke syndrome or apparent so-called focal cerebritis, cardiac 
emboli remain the most likely etiology, mandating echocardiography in these 
settings as well. Transesophageal echocardiography may be helpful in selected 
cases.29 
Strokes and leukoaraiosis were more common in the APLS group, 
consistent with the idea of an APLS-induced prothrombotic state. 
The carotid bifurcation may be conveniently imaged by ultrasound. 
Magnetic resonance angiography (MRA) or transcranial Doppler 
ultrasound confirm thrombotic lesions of extracranial or intracranial vessels. 
Cerebral vasculitis can only be detected by conventional contrast 
angiography. However, even this study often misses the predominantly small 
vessel involvement of lupus vasculopathy. 
In patients with SLE who have myelopathy, spinal MRI or myelography 
is mandatory to exclude compressive lesions. MRI also may demonstrate 
intramedullary spinal lesions, with variable sensitivity that depends on imaging 
sequences and technical factors related to the MRI equipment. If myelography 
is elected, CSF should be obtained prior to contrast introduction to assess for 
SLE disease activity, cytology, or evidence of opportunistic infection as 
appropriate.29 
Other Tests 
Electroencephalography (EEG) may be helpful to confirm the focal 
point of an apparently diffuse encephalopathy. It is most useful in patients with 
seizures whose cases are difficult to manage. 
EEG also provides a measure of recurrence risk when anticonvulsant 
therapy is withdrawn. An active spike focus (especially with multiple loci), 
frequent discharges, or localization to the frontotemporal region predicts a 
likely recurrence of seizures after anticonvulsant cessation. A normal EEG, 
even with sleep deprivation, does not exclude the possibility of recurrent 
seizures. It generally is associated with a reduced recurrence risk, although this 
has not been studied specifically in CNS lupus.30 Reported selective left 
temporolimbic region changes  are not always observed. 
EMG and nerve conduction studies (NCS) provide useful data in the 
clinical assessment of peripheral complications of SLE. 
Muscle weakness in patients with SLE may result from inflammatory 
myopathy, medication-induced myopathy, neuromuscular junction dysfunction, 
neuropathies, or from other musculoskeletal disturbances. While much of the 
clinical decision-making relies on examination and historical evidence 
(especially time course of drug therapy with steroids or hydroxychloroquine), 
EMG may be useful in distinguishing inflammatory from noninflammatory 
myopathy. 
Lupus myositis resembles dermatomyositis or polymyositis on EMG 
findings, including increased insertional activity, fibrillations and positive sharp 
waves, and myopathic motor unit potentials and recruitment patterns, as well as 
complex repetitive discharges. Lupus myositis may present with normal EMG 
findings, especially (but not exclusively) if partially treated, so that a normal 
needle examination does not exclude inflammatory myositis in SLE. 
Repetitive stimulation studies may be used to search for neuromuscular 
junction pathology analogous to that seen with either myasthenia or myasthenic 
syndrome. (This is rare in SLE but has been reported.) 
Peripheral nerve dysfunction in SLE presents clinically as mononeuritis 
multiplex, symmetrical distal polyneuropathy (sensory or sensorimotor), or 
acute demyelinating polyradiculopathy. The typical findings of each of these 
conditions may be demonstrated on conventional nerve conduction studies. As 
with other causes of acute polyradiculopathy, proximal nerve conduction 
studies or F and H wave studies may be needed to demonstrate proximal 
dysfunction, especially early in the course of the disease. 
Procedures 
Nerve biopsy may be helpful in determining an initial diagnosis of active 
vasculitis when clinical findings are ambiguous because of the relatively high 
yield of nerve biopsy in early clinical vasculitis. However, in many cases of 
clinically confluent, symmetric polyneuropathy, the predominant pathology 
may be nonspecific demyelination, reducing the clinical value of the procedure. 
When more than one potential etiology is present in the case of a disabling 
polyneuropathy, biopsy may determine the predominant pathology, serving as a 
potential alternative to empiric treatment for one or more etiologies.  
Muscle biopsy may provide the only reliable differentiation between 
inflammatory and medication-induced myopathy.41 Clinical evolution and 
medication history are most reliable, as creatine kinase is usually, but not 
always, elevated in inflammatory myopathy. EMG is usually, but not always, 
abnormal in inflammatory myopathy, and both are usually normal in 
medication-induced myopathy. When other factors are ambiguous and empiric 
therapy is impractical, then muscle biopsy is appropriate. Brain biopsy and 
Meningeal biopsy are done in rare circumstances.  
Histologic Findings 
In nerve biopsies, active necrotizing vasculitis may involve epineurial 
arterioles. Often perivascular infiltrates are found without frank arterial 
necrosis. Immunofluorescent staining may demonstrate immunoglobulin or 
complement deposition on vessel walls. 
At times, the only findings are nonspecific demyelination or nerve fiber 
dropout. 
Muscle biopsy most commonly reveals similar findings, emphasizing 
vascular and perivascular inflammation, similar to the muscle pathology in 
dermatomyositis. Less frequently, a pathology analogous to classic 
polymyositis is found, with inflammatory and other changes centered more on 
the muscle fibers, including frank necrosis, phagocytosis, and degeneration and 
regeneration of type I and II fibers. 
 
 
 
Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) 
 
NS lupus is a serious but potentially treatable illness, which, still presents 
very difficult diagnostic challenges. It is in the differential diagnosis for many 
neurological conditions. Neurologists need to be aware of the various 
presentations and neurologic complications of SLE, as patients with SLE often 
have neurologic symptoms and SLE is sometimes diagnosed after patients 
present for treatment of a neurologic event 4,5 
The prevalence of NPSLE ranges widely between 14 and 75%, reflecting 
variable diagnostic criteria and differences in selection of patients for study. 
The ACR has recently developed a standardized nomenclature system which 
provides case definitions for 19 NP syndromes seen in SLE, including reporting 
standards and recommendations for laboratory and imaging tests.50 
The Neuropsychiatric syndromes in Systemis Lupus Erythematosus according to 
the American College of Rheumatology nomenclature and case definitions5,50 
 
1. Acute confusional state (Delirium)50 
Disturbance of consciousness or level of arousal characterized by reduced 
ability to focus, maintain, or shift attention, and accompanied by disturbances 
of cognition, mood, affect, and/or behavior. The disturbances typically develop 
over hours to days and tend to fluctuate during the course of the day. They 
include hypo- and hyperaroused states and encompass the spectrum from 
delirium to coma. 
Diagnostic criteria: 
Disturbance of consciousness or level of arousal with reduced ability to 
focus, maintain, or shift attention, and one or more of the following developing 
over a short period of time (hours to days) and tending to fluctuate during the 
course of the day: 
a. Acute or subacute change in cognition that may include memory 
deficit and disorientation. 
b. A change in behavior, mood, or affect (e.g., restlessness, overactivity, 
irritability, apathy, anxiety, mood lability, etc.). 
Exclusions: 
• Primary mental/neurological disorder not related to SLE. 
• Metabolic disturbances (including glucose, electrolytes, fluid, osmolarity). 
• Substance or drug-induced delirium (including withdrawal). 
• Cerebral infections. 
2. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)50 
Diagnostic criteria: 
a. Clinical features 
i. Progressive polyradiculoneuropathy, usually ascending and 
predominantly motor, which peaks usually within 21 days or less. 
ii. Reflex loss. 
iii. Symmetric, may involve the trunk and may cause respiratory failure. 
b. Cerebrospinal fluid(CSF) i. Increased CSF protein without pleocytosis. 
c. Supportive evidence by nerve conduction study including F-wave 
ascertainment whereby there is one abnormality in three nerves.  The 
abnormalities are: 
i. Conduction block in which the amplitude of compound muscle action 
potential diminishes with more proximal sites of nerve stimulation. 
ii. F waves may be absent or prolonged. 
iii. Slowing of conduction velocity. 
iv. Prolongation of distal latencies. 
Exclusions: 
• Acute spinal cord disease. 
• Botulism. 
• Poliomyelitis and other infections. 
• Acute myasthenia gravis. 
3. Anxiety disorder50 
Anticipation of danger or misfortune accompanied by apprehension, 
dysphoria, or tension. Includes generalized anxiety, panic disorder, panic 
attacks, and obsessive-compulsive disorders. 
Diagnostic criteria: 
Both of the following: 
a. Prominent anxiety, panic disorder, panic attacks, or obsessions or 
compulsions. 
b. Disturbance causes clinically significant distress or impaired social, 
occupational, or other important functioning. 
 
4. Aseptic Meningitis 
Diagnostic criteria: All the following: 
a. Acute or subacute onset of headache with photophobia, neck stiffness, 
and fever. 
b. Signs of meningeal irritation. 
c. Abnormal CSF. 
 
 
 
5. Autonomic disorder50 
Disorder of the autonomic nervous system with orthostatic hypotension, 
sphincteric erectile/ejaculatory dysfunction, anhidrosis, heat intolerance, 
constipation. 
Diagnostic criteria: 
Symptoms and abnormal response to provocative tests: 
Test normal range 
a. Blood pressure response to standing: fall in blood pressure more than 
30/15 mmHg or vertical tilt (systolic/diastolic). 
b. Heart rate response to standing: increases 11–29 beats/minute. 
c. Heart rate variation with respiration: maximum–minimum heart rate: 
15 beats/minute; E:I ratio (ratio of heart rate during expiration and 
inspiration): 1:2. 
c. Valsalva ratio: 1:4. 
d. Sweat test: Sweating over all body and limbs. 
6. Cerebrovascular disease  
Diagnostic criteria: 
One of the following and supporting radioimaging study: 
a. Stroke syndrome: acute focal neurological deficit persisting more than 24 
hours (or lasting less than 24 hours with computed tomography (CT) or 
magnetic resonance imaging (MRI) abnormality consistent with physical 
findings/symptoms. 
b. Transient ischemic attack: acute, focal neurological deficit with clinical 
resolution within 24 hours (without corresponding lesion on CT or MRI). 
c. Chronic multifocal disease: recurrent or progressive neurological 
deterioration attributable to cerebrovascular disease. 
d. Subarachnoid and intracranial hemorrhage: bleeding documented by CSF 
findings, MRI/CT. 
e. Sinus thrombosis: Acute, focal neurological deficit in the presence of 
increased intracranial pressure. 
Note: The finding of unidentified bright objects on MRI without clinical 
manifestations is not classified at the present time. 
 
7. Cognitive Dysfunction:50  Significant deficits in any or all of the following 
cognitive functions: simple or complex attention, reasoning, executive skills 
(e.g., planning, organizing, sequencing), memory (e.g., learning and recall), 
visuospatial processing, language (e.g., verbal fluency), and psychomotor 
speed. Cognitive dysfunction implies a decline from a higher level of 
functioning and ranges from mild impairment to severe dementia. It may or 
may not impede social, educational, or occupational functioning, depending on 
the function(s) impaired and the severity of impairment. Subjective complaints 
of cognitive dysfunction are common and may not be objectively verifiable. 
Neuropsychological testing should be done in suspected cognitive dysfunction, 
and its interpretation should be done with a neuropsychologist. 
Diagnostic criteria: 
a. Documented impairment in one or more of the following cognitive domains: 
i. Simple attention. 
ii. Complex attention. 
iii. Memory (e.g., learning and recall). 
iv. Visuospatial processing. 
v. Language (e.g., verbal fluency). 
vi. Reasoning/problem solving. 
vii. Psychomotor speed. 
viii. Executive functions (e.g., planning, organizing, and sequencing). 
b. The cognitive deficits represent a significant decline from a former level of 
functioning (if known).  
c. The cognitive deficits may cause varying degrees of impairment in social, 
educational, or occupational functioning, depending on the function(s) impaired 
and the degree of impairment. 
 
8. Demyelinating syndrome50  
Diagnostic criteria: 
Two or more of the following, each occurring at different times, or one of the 
following occurring on at least two different occasions: 
a. Multiple discrete areas of damage to white matter within CNS, causing 
one or more limbs to become weak with sensory loss. 
b. Transverse myelopathy. 
c. Optic neuropathy. 
d. Diplopia because of isolated nerve palsies or internuclear 
ophthalmoplegia. 
e. Brain stem disease with vertigo, vomiting, ataxia, dysarthria, or 
dysphagia. 
f. Other cranial nerve palsies. 
 
9. Headache  
a. Migraine 
i. Migraine without aura: Idiopathic, recurrent headache manifested by 
attacks lasting 4–72 hours. Typical characteristics are unilateral 
location, pulsating quality, moderate-to-severe intensity, aggravation 
by routine physical activity, and associated with nausea, vomiting, 
photo- and phonophobia. At least five attacks fulfilling the 
aforementioned criteria. 
ii. Migraine with aura: Idiopathic, recurrent disorder manifested by 
attacks of neurological symptoms localizable to cerebral cortex or 
brain stem, usually gradually developing over 5–20 minutes and 
lasting less than 60 minutes. Headache, nausea, and/or photophobia 
usually follow neurologic aura symptoms directly or after an interval 
of less than 1 hour. Headache usually lasts 4–72 hours, but may be 
completely absent. 
b. Tension headache (episodic tension-type headache). 
Recurrent episodes of headaches lasting minutes to days. Pain typically 
pressing/tightening in quality, of mild-to-moderate intensity, bilateral in 
location, and does not worsen with routine physical activity. Nausea is rare, but 
photophobia and phonophobia may be present. At least 10 previous headaches 
fulfilling these criteria 
c. Cluster headache. 
Attacks of severe, strictly unilateral pain, orbital, supraorbital, and/or temporal, 
usually lasting 15–180 minutes and occurring from at least once every other day 
up to eight times per day. Associated with one or more of the following: 
conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and 
facial sweating, miosis, ptosis, eyelid edema. Attacks occur in series for weeks 
or months (“cluster” periods), separated by remissions of usually months or 
years. 
d. Headache from intracranial hypertension (also called pseudotumor cerebri, 
benign intracranial hypertension. All of the following: 
i. Increased intracranial pressure (200 mm H2O) measured by lumbar 
puncture. 
ii. Normal neurological findings, except for papilledema and possible 
nerve VI palsy. 
iii. No mass lesion and no ventricular enlargement on neuroimaging. 
iv. Normal or low protein and normal white cell count in CSF. 
v. No evidence of venous sinus thrombosis. 
e. Intractable headache, nonspecific. 
 
10. Mononeuropathy (single/multiplex) 50 
Disturbed function of one or more peripheral nerve(s) resulting in 
weakness/paralysis or sensory dysfunction because of either conduction block 
in motor nerve fibers or axonal loss. Conduction block is related to 
demyelination with preservation of axon continuity. Remyelination may be 
rapid and complete. If axonal interruption takes place, axonal degeneration 
occurs below the site of interruption and recovery is often slow and incomplete. 
Sensory symptoms and sensory loss may affect all modalities or be restricted to 
certain forms of sensation. 
Diagnostic criteria: 
a. Clinical demonstration of motor/sensory disturbances in the distribution 
of a peripheral nerve and/or 
b. Abnormalities on nerve conduction studies or electromyogram (EMG) 
(i.e., concentric needle examination). 
 
11. Mood disorders50 
Prominent and persistent disturbance in mood characterized by: 
• Depressed mood or markedly diminished interest or pleasure in almost 
all activities or 
• Elevated, expansive or irritable mood. 
Diagnostic criteria: 
a. Major depressive-like episode. 
One or more major depressive episodes with at least five of the following 
symptoms, including either i or ii or both, during a 2-week period and nearly 
every day: 
i. Depressed mood most of the day, by subjective report or observation made 
by others. ii. Markedly diminished interest or pleasure in all, or almost all, 
activities most of the day, by subjective report or observation made by others. 
iii. (1) Significant weight loss without dieting or weight gain (>5% of body 
weight in 1 month). 
(2) Insomnia or hypersomnia. Psychomotor agitation or retardation 
(observable by others, not merely subjective feeling of restlessness or being 
slowed down). 
(3) Fatigue or loss of energy. 
(4) Feelings of worthlessness or excessive or inappropriate guilt (may be 
delusional). 
(5) Diminished ability to think or concentrate, or indecisiveness. 
(6) Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or a specific plan for 
committing suicide. 
b. Mood disorder with depressive features. 
All of the following: 
i. Prominent and persistent mood disturbance characterized by 
predominantly depressed mood or markedly diminished interest or 
pleasure in all, or almost all, activities. 
ii. Full criteria for major depressive-like episode are not met. 
c. Mood disorder with manic features. 
i. Prominent and persistent mood disturbance characterized by 
predominantly elevated, expansive or irritable mood. 
d. Mood disorder with mixed features. 
i. Prominent and persistent mood disturbance characterized by symptoms 
of both depression and mania; neither predominates. 
 
For all mood disorders: Symptoms must cause significant distress or 
impairment in social, occupational, or other important areas of functioning. 
 
12. Movement disorder (chorea) 50 
Chorea: Irregular, involuntary brief and unpredictable, jerky movements that 
may involve any portion of the body in random sequence 
Diagnostic criteria: 
Both of the following: 
a. Observed abnormal movements. 
b. Random, unpredictable sequence of movements. 
 
 
13. Myasthenia gravis 50 
Neuromuscular transmission disorder characterized by fluctuating weakness 
and fatigability of bulbar and other voluntary muscles without loss of reflexes 
or impairment of sensation or other neurological function. Myasthenia gravis is 
an autoimmune disorder mediated by antibodies to acetylcholine receptors. It 
may occur with other diseases of immunological origin. 
Diagnostic criteria: 
a. Characteristic signs and symptoms include one or more of the following: 
i. Diplopia, ptosis, dysarthria, weakness in chewing, difficulty in 
swallowing, muscle weakness with preserved deep tendon reflexes, and, 
less commonly, weakness of neck extension and flexion, and weakness of 
trunk muscles. 
ii. Increased weakness during exercise and repetitive use with at least 
partially restored strength after periods of rest. 
iii. Dramatic improvement in strength following administration of 
anticholinesterase drug (edrophonium and neostigmine). 
And one or more of the following: 
b. EMG and repetitive stimulation of a peripheral nerve: In myasthenia gravis, 
repetitive stimulation at a rate of two per second shows characteristic 
decremental response that is reversed by edrophonium or neostigmine. Single-
fiber studies show increased jitter. 
c. Antibodies to acetylcholine receptors. 
 
14. Myelopathy50 
Diagnostic criteria: 
Usually rapid onset (hours or days) of one or more of the following: 
a. Bilateral weakness of legs with or without arms 
(paraplegia/quadriplegia); may be asymmetric. 
b. Sensory impairment with cord level similar to that of motor weakness, 
with or without bowel and bladder dysfunction. 
 
15. Neuropathy, cranial50 
Diagnostic criteria: 
Syndrome corresponding to specific nerve function: 
a. Olfactory nerve: loss of sense of smell, distortion of smell, and loss of 
olfactory discrimination. 
b. Optic nerve: decrease or loss of visual acuity, diminished color 
perception, afferent pupillary defect, and visual field deficits. 
c. Oculomotor nerve: ptosis of the upper eyelid and inability to rotate eye 
upward, downward, or inward (complete lesion), and/or dilated 
nonreactive pupil and paralysis of accommodation (interruption of 
parasympathetic fibers only). 
d. Trochlear nerve: extorsion and weakness of downward movement of 
affected eye. 
e. Abducens nerve: weakness of eye abduction. 
f. Trigeminal nerve: paroxysm of pain in lips, gums, cheek, or chin initiated 
by stimuli in trigger zone (trigeminal neuralgia) and sensory loss of the 
face or weakness of jaw muscles. 
g. Facial nerve: unilateral or bilateral paralysis of facial expression muscles, 
or impairment of taste, or hyperacusis (painful sensitivity to sounds). 
h. Vestibulo-cochlear nerve: deafness, tinnitus (cochlear), dizziness, and/or 
vertigo (vestibular). 
i. Glossopharyngeal nerve: swallowing difficulty, deviation of soft palate to 
normal side, anesthesia of posterior pharynx and/or glossopharyngeal 
neuralgia (unilateral stabbing pain in root of tongue and throat, triggered 
by coughing, sneezing, swallowing, and pressure on ear tragus). 
j. Vagus nerve: soft palate droop, loss of the gag reflex, hoarseness, nasal 
voice, and/or loss of sensation at external auditory meatus. 
k. Accessory nerve: weakness and atrophy of sternocleidomastoid muscle 
and upper part of trapezius muscle. 
l. Hypoglossal nerve: paralysis of one side of tongue with deviation to the 
affected side. 
 
16. Plexopathy50 
Disorder of brachial or lumbosacral plexus producing muscle weakness, 
sensory deficit, and/or reflex change not corresponding to the territory of single 
root or nerve. 
Diagnostic criteria: 
All of the following: 
a. Characteristic signs and symptoms: 
i. Brachial plexus: deep pain in shoulder, muscle weakness, sensory 
deficit and/or reflex impairment of arm, or 
ii. Lumbosacral plexus: deep boring pain in thigh, muscle weakness, 
sensory deficit, and/or reflex impairment of leg. 
b. Positive EMG finding (concentric needle examination) and/or nerve 
conduction studies for EMG: more than one root or nerve abnormalities with 
sparing of paraspinal muscles for nerve conduction study: absent or reduced 
amplitude on motor or sensory nerve conduction. 
c. Normal MRI or CT scan (optional: myelogram) to rule out a higher 
neurological lesion. 
 
17. Polyneuropathy50 
Acute or chronic disorder of sensory and motor peripheral nerves with 
variable tempo characterized by symmetry of symptoms and physical findings 
in a distal distribution. 
Diagnostic criteria: 
One or both of the following: 
a. Clinical manifestations: 
i. Clinical demonstration of distal sensory and/or motor deficit. 
ii. Symmetry of signs/symptoms, and/or. 
b. Confirmation by EMG: 
i. Concentric needle examination demonstrating denervation of muscle, 
or 
ii. Nerve conduction study demonstrating axonal or demyelinating 
neuropathy. 
 
 
 
18. Psychosis50 
Severe disturbance in the perception of reality characterized by delusions and/or 
hallucinations 
Diagnostic criteria: 
All of the following: 
a. At least one of the following: 
i. Delusions. 
ii. Hallucinations without insight. 
b. The disturbance causes clinical distress or impairment in social, occupational, 
or other relevant areas of functioning. 
c. The disturbance does not occur exclusively during the course of a delirium. 
d. The disturbance is not better accounted for by another mental disorder (e.g., 
mania). 
 
19. Seizures and seizure disorders 
Abnormal paroxysmal neuronal discharge in the brain causing abnormal 
function. Seizures are divided into partial and generalized. Partial seizures have 
clinical or electroencephalographic evidence of a focal onset; the abnormal 
discharge usually arises in a portion of one hemisphere and may spread to the 
rest of the brain during a seizure. Primary generalized seizures have no 
interictal evidence of focal onset on electroencephalogram (EEG). A 
generalized seizure can be primary or secondary. 
a. Primary generalized seizures (bilaterally symmetric and without local onset). 
i. Tonic clonic (grand mal) or tonic or clonic. 
ii. Atonic or astatic seizures. 
iii. Absence seizures (petit mal). 
iv. Myoclonic seizures. 
b. Partial or focal seizures (seizures beginning locally) (also referred to as 
Jacksonian, temporal lobe, or psychomotor seizure, according to type). 
i. Simple, without impairment of consciousness. (motor, sensory, aphasic, 
cognitive, affective, dysmnesic, illusional, olfactory, or psychological). 
ii. Complex, with partial impairment of consciousness 
iii. Simple or complex may evolve to secondary generalized tonic/clonic 
seizures.  
Diagnostic criteria: 
a. Independent description by a reliable witness. 
b. EEG abnormalities 
 
 
 
 
Treatment 
 
Medical Care 
Treatment of systemic lupus erythematosus (SLE) should be provided in 
cooperation with a consulting rheumatologist. Therapeutic intensity correlates 
with the severity of an acute attack. NSAIDs and other symptomatic agents are 
used for less threatening symptoms. Corticosteroids are used in low-dose oral, 
high-dose oral, or high-dose IV regimens according to the severity of potential 
organ damage.4 
Clinical studies supporting this approach were generally performed in 
lupus nephritis because of its frequency, severity, and quantifiable improvement 
or deterioration, but the same treatment approaches are generally applied to 
other organ systems, including the central and peripheral nervous systems and 
muscular disease. This overall treatment approach should be familiar to 
neurologists who are accustomed to the evaluation and treatment of other 
autoimmune conditions such as multiple sclerosis, myasthenia gravis, 
or polymyositis.5 
With little evidence base to the therapeutic modalities, a logical approach 
to the treatment of cerebral lupus is to build a treatment strategy around the 
various possible pathogeneses: (1) ischemia due to thromboses secondary to the 
antiphospholipid syndrome, (2) small-vessel noninflammatory proliferative 
vasculopathy due to cell-mediated immune mechanisms, and (3) antibody-
mediated damage to spinal cord and optic nerve—akin to Devic disease.31 
The standard treatment for the non-thrombotic syndromes associated with 
SLE is immunosuppression, first with corticosteroids and with early recourse to 
cyclophosphamide. A Cochrane Database Systematic Review found no 
randomized controlled trials comparing these two treatments and concluded 
there was no evidence of a treatment advantage of cyclophosphamide.32 
High-dose IV corticosteroid regimens consist of methylprednisolone 1-2 
g daily for 3-6 doses, followed by oral prednisone 60 mg daily, then tapering 
according to clinical recovery. Less threatening flare-ups may be treated with as 
much as 100 mg or as little as 10 mg prednisone PO qd (or other agents in 
equivalent dosage), again tapering gradually according to clinical symptoms, 
with an increase of 10-20% during the taper if clinical disease flares again. 
Tapering to an every other day steroid regimen reduces adverse effects 
substantially but probably will not be successful until clinical disease is quite 
stable. In acute high dosage, steroids may provoke status epilepticus, psychosis, 
hypokalemia, hyperglycemia, or hypertension and clinical evidence of any 
intercurrent infection may be reduced.4 
With chronic use, steroids cause familiar adverse effects including weight 
gain, diabetes mellitus, cataracts, immunocompromise, and osteoporosis. 
Calcium supplementation (1 g daily for men or premenopausal women, 1.5 g 
daily for postmenopausal women) should be initiated early and continued even 
when steroids are tapered successfully to qod. 
The discovery that Toll-like receptor signaling and interferon-alpha 
abundance are central elements of the disease process has led to a new 
appreciation for hydroxychloroquine as an essential baseline medication. 
Modulation of the immune system via B-cell depletion is entering clinical 
practice. Mycophenolate mofetil is an effective and safer alternative to 
cyclophosphamide for patients with lupus nephritis. Other therapeutic 
approaches under development include anticytokine therapies, co-stimulatory 
blockade, antigen-specific immune modulation, and hematopoietic stem cell 
transplantation.33 
Various steroid-sparing strategies have evolved for long-term use, 
including cyclophosphamide 0.5-2 mg/kg/d, azathioprine 1-2 mg/kg/d, and 
methotrexate 10-15 mg given once weekly with folate rescue, permitting 
gradual reduction or elimination of chronic steroid therapy. Higher dose ranges 
or dosing based on body surface area may be used for these medications based 
on the experience of individual clinicians. 
All chronic cytotoxic regimens present substantial risks and should be 
followed only by physicians familiar with these agents. In acute, life-
threatening illness, one option is to initiate cyclophosphamide PO or a single 
dose of 8-20 mg/kg IV, along with IV methylprednisolone.1,4 
Jonsdottir et al (2008) reported that the majority of patients improved 
following rituximab plus cyclophosphamide.34  The differential downregulation 
of anti-DNA of the IgG and IgA but not the IgM isotypes supports the 
hypothesis that cells producing pathogenic autoantibodies are preferentially 
targeted by the treatment. The fact that greater absolute numbers of CD19+ cells 
at baseline predict a less impressive clinical and serological response suggests 
that more flexible dosing could be advantageous. 
Antimalarials, especially hydroxychloroquine in dosage of 100-400 mg 
daily, are used as alternatives to steroids or as supplements to accelerate steroid 
taper. They have not been studied in central or peripheral nervous system 
disease. Antimalarials generally require months to become effective, and, 
therefore, they are not used in the acute treatment of organ-threatening 
disease.35 
Generally, mild myopathy or polyneuropathy may be treated with 
NSAIDs and other symptomatic medications (eg, anticonvulsants, tricyclics, 
other medications used for neurogenic or musculoskeletal pain). Symptoms 
may be caused by medications (eg, steroids, antimalarials) or other etiologies in 
addition to SLE. If alternative explanations are unlikely and symptoms are more 
bothersome, low-to-medium dose prednisone may be tried, possibly with a 
longer-term transfer to antimalarial therapy.36 
If a patient with SLE presents with acute polyradiculopathy resembling 
Guillain-Barré syndrome or chronic relapsing polyradiculopathy resembling 
chronic inflammatory demyelinating polyneuropathy, treatment with IV 
immunoglobulin (IVG) in conventional doses should be considered. When IVG 
is unavailable or poorly tolerated, plasma exchange should be considered as an 
alternative. Unfortunately, few therapeutic studies exist on these rare 
presentations of SLE. 
Seizures are common sequelae of SLE and may result from acute or 
chronic disease. Acute electrolyte disturbance, response to high-dose steroids, 
or other acute disturbance may only require temporary anticonvulsant 
treatment, while more chronic epileptogenic foci may require lifetime 
prophylaxis. Anticonvulsants may be used in a conventional fashion, 
emphasizing medications most effective for focal onset or secondarily 
generalized seizures. Phenytoin and other agents associated with drug-induced 
lupus are unlikely to actually increase disease activity in SLE, but with chronic 
use may cause diagnostic confusion for physicians.1,4 
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Treatment of the antiphospholipid syndrome remains controversial, with 
therapy based predominantly on anecdotal experience. Although many 
authorities recommend full anticoagulation with warfarin (Coumadin) (although 
there is no randomized clinical trial to prove this), other authorities support 
antiplatelet therapy initially, with stronger measures reserved for repeated 
stroke, progressive myelopathy, or other clear-cut, clinical treatment failure.4 It 
is clear that aiming for an INR of 2.0–3.0 is as good as at reducing the risk of 
further events than more intensive anticoagulation. This could be done possibly 
in conjunction with immunosuppressant therapy to suppress production of the 
antibody. 
Cerebral lupus, like the neurological vasculitides, is best managed jointly 
by neurologists, clinical immunologists, renal physicians, rheumatologists and 
the primary physicians.1,4 
 
Prognosis 
• Overall, prognosis for SLE patients has improved dramatically in recent 
decades, with 70% now living 10 years after diagnosis.4 
• Neurologic complications worsen prognosis, especially in the presence of 
refractory seizures, encephalopathy, or paralysis from stroke or 
myelopathy. 
• CNS-specific statistics are not available. 
• Active SLE prior to pregnancy is associated with a less favorable 
maternal and fetal outcome. Hypertension increased the risk of fetal loss 
and adverse outcome. Phadungkiatwattana et al reported that 
preeclampsia was the most common maternal complication (20.6%) 36 
 
 
 
MATERIALS AND METHODS 
 
 
Design of the Study : Cross-sectional and observational study 
Study Centre : Institute of Neurology, Madras Medical College and 
Government General Hospital, Chennai-3. 
Study Period : January 2009 to April 2010 
 
Material and selection of subjects:  
Consecutive patients who got admitted in Department of Rheumatology 
or in medical/speciality wards who fit into the ACR criteria for SLE 
 
Exclusion criteria  
1. Children below 12 years of age 
2. Patients with other comorbid conditions like diabetes, hyperlipidemia, 
overlap syndromes, cardiac diseases, previous neurologic diseases not 
related to SLE. 
3. Patients who do not satisfy the 1997 Revised Criteria13 for the 
Classification of Systemic Lupus Erythematosus (SLE) 
STUDY PROCEDURE: 
Ethical Consideration: 
 The study was commenced after obtaining approval from the Institutional 
Ethical Committee. Patients who were admitted in the Rheumatology, medical 
or speciality wards were included in the study. Written informed consent was 
obtained from those who were willing to participate in the study in the 
prescribed format in the regional language. Left thumb impression was obtained 
from those patients who are illiterate. 
SCREENING: 
Apart from age and sex, detailed medical history including mode of 
onset, duration of illness, constitutional, musculoskeletal, mucocutaneous, 
renal, cardiac, respiratory symptoms were obtained apart from neurological 
symptoms. Symptoms pertaining to the central or peripheral nervous system 
involvement like headache, seizures, altered sensorium, behavioural 
disturbances, cranial nerve disturbances, motor disturbances, sensory 
disturbances, autonomic disturbances, involuntary movements, psychiatric 
symptoms were obtained in detail from the patient or their attenders. Previous 
records were verified and data collected.  
Detailed general examination and neurological examination were 
performed in all patients. Cognitive involvement could not be studied in detail 
in these patients because of technical reasons. Cognitive assessment requires 
neuropsychological assessment. This is time consuming (1-4 h as recommended 
by ACR) and needs wholehearted co-operation, which was not readily 
forthcoming in this cohort of sick patients.6 Presence of aphasia, psychosis etc 
also interfered with assessment. Earlier series, which were hospital based did 
not give much importance to cognitive impairment.6,8 Mini Mental State 
Examination(MMSE) scores were obtained in all conscious patients. 
Neuropsychiatric syndromes were classified as defined by the ACR.50 
Medical reports were analyzed and NP syndromes diagnosed earlier were also 
included. Even though the ACR classification lists out the investigations 
required to make the diagnosis of each NPSLE syndrome, only those 
investigations, which were of prime importance to make a diagnosis were done. 
Serology: 
Anti Nuclear Antibody(ANA) testing was obtained from all patients. Anti 
body to Double stranded DNA(Anti-dsDNA) was obtaines from selected 
patients. Cut- off value for ANA: 
 
 
 
 
ANA result Interpretation
<10.0 Negative 
≥10.0 Positive 
Cut off value for Anti-ds DNA 
Value (IU/mL) Interpretation 
<30 Negative 
30 – 75 Borderline Positive 
>75 Positive 
 
Imaging: 
Atleast one imaging of either CT Brain or MRI or both was done on all 
patients who were suspected to have CNS lupus. 
Nerve Conduction Studies: 
Routine Nerve conduction studies(NCS) were done in all patients. The 
studies included motor and sensory conduction of bilateral ulnar, median, tibial 
and peroneal nerves including latency, amplitude, conduction velocity and F 
wave latencies. NCS of selected nerves and Electromyography(EMG) was done 
in selected patients who had abnormal routine nerve conduction studies. EMG 
was also done for patients who had features of myopathy. 
Nerve Biopsy: 
Nerve Biopsy of Sural Nerve was done only in two patients who had 
abnormal nerve conduction. Some patients did not consent for a nerve biopsy. 
The biopsy specimen were sent to Department of Neuropathology at 
NIMHANS, Bangalore for Histopathological evaluation. 
 
EEG: 
Routine EEG was done in patients who were suspected to have seizures. 
A EEG study consisted of awake EEG with activation procedures which 
included sleep deprivation, sleep record of 20 minutes, hyperventilation and 
photic responses(upto 24Hz). The seizure patients were classified based on 
clinical semiology and EEG patterns.  
 
CSF analysis: 
CSF analysis for biochemical profiles(protein, sugar), gram stain and cell 
count were done in selected cases. The primary aim was to exclude a infection 
or a primary demyelination. 
 
DSM IV criteria was applied to categorize patients who had features of 
psychosis and anxiety.  
To analyse the patients for features of depression, Hamilton Rating Scale 
(HAM 21) questionnaire was employed in all patients and the patients were 
categoried as mild, moderate or severe depression. 
 Hamilton Rating Scale for Depression (HAM 21) 
A 21 point questionnaire(see Annexure II) was employed and all the patients 
were assessed for the presence or absence of depression and interpreted based 
on the scores obtained as shown below: 
SCORE INTERPRETATION 
0 to 6 Normal 
7 to 17 Mild Depression 
18 to 24 Moderate Depression 
>24 Severe Depression 
 
Statistical Analysis: 
The statistical analysis was performed using SPSS software, version 17.0. 
Results are presented as the mean ± S.D., except for frequencies, which are 
expressed as percentages. Comparison between groups were  made by means of 
Chi square test used when appropriate. P values less than 0.05 were considered 
significant. Graphs were produced using Microsoft Excel. 
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Duration of Illness: 
Four patients(9.5%) presented with neurologic symptoms as the first 
manifestations of the illness. The maximum duration was 11 years. The mean 
duration was 3.16 years. Median was 3. The mode was 2 years.  The 
distribution of duration of illness of SLE in the studied patients is as follows: 
Duration 
(years) No of patients 
Percentage 
n=42(100%) 
0 4 9.5% 
1 7 16.6% 
2 8 19% 
3 7 16.6% 
4 4 9.5% 
5 7 16.6% 
>5yrs 5 12% 
TOTAL 42 100% 
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ACR criteria of SLE during presentation: 
 Though 4 out of the 11 of the revised ACR criteria has to be fulfilled for 
entry into the study many patients fulfilled even more than 4 criteria. The 
distribution is as follows: 
ACR criteria 
(out of 11) 
No of patients 
(Total n=42) Percentage 
4 30 71.4% 
5 7 16.6% 
6 3 7.2% 
≥7 2 4.8% 
 
Skin manifestations was the commonest association seen in 71.4%(n=30) 
of patients followed by nephritis in 33.3%(n=14) among those who had atleast 
one NPSLE manifestation. 
Serology:  
ANA was positive in all the patients(100% positivity, n=42). Anti dsDNA was 
positive in 20 patients among 32 patients who did the testing.(62.5% positivity) 
Imaging: 
Of the 42 patients, 30(71%) patients had done CT scan of brain, 8(19%) 
patients did MRI and four(10%) did both CT and MRI brain. An abnormal 
imaging had a significant correlation with CVA ( P <0.0001) and a normal 
imaging has significant correlation with psychosis ( P <0.0001). 
 
NEUROPSYCHIATRIC MANIFESTATIONS: (NPSLE) 
NPSLE SYNDROMES No of patients Percentage 
CENTRAL NERVOUS SYSTEM 
1. Aseptic meningitis  
 - 0% 
2. Cerebrovascular disease 
 5 12% 
3. Demyelinating syndrome  
 - 0% 
4. Headache  
 23 54.7% 
5. Movement disorder  
 2 4.8% 
6. Myelopathy  
 - 0% 
7. Seizure disorders  
 14 33.3% 
8. Acute confusional state  
 
7 16.6% 
9. Anxiety disorder 
 - 0% 
10. Mood disorder(Depression) 
 20 47.6% 
11. Psychosis 
 5 12% 
PERIPHERAL NERVOUS SYSTEM 
1. Acute inflammatory demyelinating 
polyradiculo-neuropathy(AIDP) 1 2.4% 
2. Autonomic disorder - 0% 
3. Mononeuropathy, single/multiplex 3 7.2% 
4. Myasthenia gravis - 0% 
5. Neuropathy, cranial - 0% 
6. Polyneuropathy 1 2.4% 
7. Plexopathy - 0% 
8. Myositis/myopathy 6 14% 
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PERIPHERAL NERVE DISORDERS: 
• AIDP was noted in one patient(2.4%) 
• Polyneuropathy was noted in one patient(2.4%) whose sural nerve biopsy 
showed axonal changes in histopathology. 
• Carpal Tunnel Syndrome was seen in two patients(4.8%) 
• Mononeuritis Multiplex involving bilateral ulnar and right tibial nerves 
was seen in one patient(2.4%) 
MOOD DISORDERS: 
20 patients(47.6%) had mood disorders, all of whom had features of 
major depression. None had features of mania or mixed mood disorders. The 
Hamilton rating Scale for Depression was used to categorize depression into 
mild moderate and severe and those who had moderate or severe depression 
were considered to have major depressive episode. 
Hamilton Rating Scale for Depression (HAM 21) 
SCORE INTERPRETATION No. of Patients Percentage 
0 to 6 Normal 13 31% 
7 to 17 Mild Depression 9 21.4% 
18 to 24 Moderate Depression 11 26.2% 
>24 Severe Depression 9 21.4% 
TOTAL 42 100% 
MOVEMENT DISORDERS: 
Two patients (4.8%) had tremors of both hands, symmetrical, 
predominantly action induced (distal >proximal). No chorea was noted in the 
studied patients. 
TREATMENT: 
All patients were treated with steroids initially. Methylprednisolone was 
instituted in some of them while others received oral steroids(Prednisolone). 
The dose of Methyprednisolone was 1 gram per day for five days followed by 
oral steroids. The dose of oral prednisolone was 1mg/kg body weight.  
Eight(19%) of the chronic patients especially those with associated lupus 
nephritis and the patient with polyneuropathy were started on 
Cycophosphamide at a dose of 500 to 750 mg/m2 in divided doses for 3 days 
every month. Methotrexate and Hydroxychloroquine were also initiated in some 
patients. Disease specific treatments were instituted for the NPSLE syndromes 
(viz. antiepileptics, antiplatelets, anticoagulants, NSAIDs, antidepressants, 
antipsychotics) 
No mortality was noted till discharge. The cerebrovascular disease 
patients and polyneuropathy patient had severe morbidity on discharge. The 
patients who presented with seizure disorder, headache, psychosis, mood 
disorders had significant improvement on discharge. 
DISCUSSION 
The prevalence of rigorously defined neuropsychiatric manifestations 
was high at study entry in our cohort as 70% of our patients had one or more 
NPSLE syndromes. 9.5% (n=4) of patients presented with NPSLE as the first 
manifestation of SLE. The study describes Neuropsychiatric syndromes 
significant enough to warrant hospitalization as well NPSLE syndromes 
occurring in SLE patients who are significantly morbid from other systemic 
illness. 
The prevalence of specific NPSLE syndromes varies widely in the 
literature. Though community based studies were available for comparison, 
hospital based studies are very few and one such study was conducted in India 
by Robert et.al. from Trivandrum.6 The other study is the San Antonio Lupus 
Study of Neuropsychiatric Disease (SALUD), by Brey et.al.7 These two studies 
were compared with the present study and the prevalence of the NPSLE 
syndromes were compared with the available data. 
The prevalence of the NPSLE among the admitted SLE patients was 70% 
in the present study. This was 78% in Robert et.al.6 (Kerala) study and 80% in 
SALUD study (Brey et.al.).7 The prevalence was almost comparable to the 
available data.   
The female to male sex ratio was 20:1 in the present study. The females 
were 100% in Robert et.al6 study whereas it was 15:1 in SALUD study.7 
The commonest NPSLE syndrome seen in this study was Headache in 
54.7% (n=23). This feature was in concordance with the other studies which 
also reported headache as the commonest presentation of  NPSLE syndromes. 
The prevalence was 55.6% in Robert et.al.6 study and 57% in SALUD study. 
The most common form of headache was migraine without aura seen in 56.5% 
patients in contrast to SALUD study where migraine with aura was the 
commonest headache seen in 42%.7 
The next most common presentation was Mood disorders noted in 47.6% 
(n=20)  patients as compared to 51% in SALUD study.7 But mood disorder was 
not seen in Robert et.al. series.  
Routine nerve conduction study done in all patients could detect 
mononeuropathies, especially carpal tunnel syndrome in two patients(4.8%). 
One patient(2.4%) had mononeuritis multiplex like presentation of bilateral 
ulnar, and right tibial nerves. The cumulative involvement of peripheral nerve 
in this study by electrophysiology is 12%(n=5). 
Cognitive involvement could not be studied in detail in these patients 
because of technical reasons. Cognitive assessment requires neuropsychological 
assessment. This is time consuming (1-4 h as recommended by ACR) and needs 
wholehearted co-operation, which was not readily forthcoming in this cohort of 
sick patients. Presence of aphasia, psychosis etc also interfered with assessment. 
Earlier series, which were hospital based did not give much importance to 
cognitive impairment. 
An interesting and new finding was the tremor disorder seen in 2 (4.8%) 
of the patients. This syndrome has not been defined in the ACR nomenclature 
and rare in literature.51 Both the patients had bilateral distal fine tremor, 
prominent during posture and action. This type of tremor can occur in essential 
tremor syndrome or as part of enhanced physiologic tremor, due to drugs or 
fatigue. Drug induced tremor could not be ruled out in any patients. It is likely 
that some or all of these factors were responsible for tremor in our patients 
either causally or as a contributory factor. The available imaging did not show 
any focal abnormalities. It is likely that this sign was not detected in many 
patients as index of suspicion was low and it did not often produce any 
symptoms. 
Cerebrovascular disease was seen in 12% of patients(n=5). Of these, 40% 
(n=2)  was Cortical Sinus Venous Thrombosis(CSVT) and 40% (n=2) was 
stroke syndromes. Robert et.al.6 from kerala reported that cerebrovascular 
disease occurred in 16.2% of patients.   
NPSLE SYNDROMES 
CENTRAL NERVOUS SYSTEM 
The present 
study  
n=42 (100%) 
Robert.et.al.6 
(Kerala) 
n=39(100%) 
Brey. et.al.7 
SALUD study 
n=128 (100%) 
1. Aseptic meningitis  
 NS NS NS 
2. Cerebrovascular disease 
 5 (12%) 6(16.2%) 2 (2%) 
3. Demyelinating syndrome  
 NS NS NS 
4. Headache  
 23 (54.7%) 20 (55.6%) 73 (57%) 
Migraine with Aura 5 (21.7%) 
10 (50%) 
31 (42%) 
Migraine without Aura 13 (56.5%) 20 (27%) 
Tension type Headache 4 (17.3%) 10 (50%) 21 (29%) 
Others 1 (4.3%) NS 1 (1%) 
5. Movement disorder  
 2 (4.8%) 9 (23.1%) 1 (1%) 
6. Myelopathy  
 NS NS NS 
7. Seizure disorders  
 14 (33.3%) 8 (20.5%) 21 (16%) 
Partial seizures 1 (7.1%) 
 
21(100%) 
Primary Generalised 10 (71.4%) NS 
Secondary Generalised 3 (21.4%) NS 
8. Acute confusional state 
 7 (16.6%) 6(16.2%) NS 
9. Anxiety disorder 
 NS NS 27 (24%) 
10. Mood 
disorder(Depression) 
 
20 (47.6%) NS 62 (51%) 
11. Psychosis 
 5 (12%) 6(16.2%) 6 (5%) 
 
NPSLE SYNDROMES 
PERIPHERAL NERVOUS SYSTEM 
The present 
study  
n=42 (100%) 
Robert.et.al.6 
(Kerala) 
n=39(100%) 
Brey. et.al.7 
SALUD study 
n=128 (100%) 
1. Acute inflammatory 
demyelinating 
polyradiculo-
neuropathy(AIDP) 
1 (2.4%) NS NS 
2. Autonomic disorder NS NS NS 
3. Mononeuropathy, 
single/multiplex 
3 (7.2%) 3 (7.9%) 9 (8%) 
4. Myasthenia gravis NS NS NS 
5. Neuropathy, cranial NS NS 2 (2%) 
6. Polyneuropathy 1 (2.4%) NS 22 (20%) 
7. Plexopathy NS NS NS 
8. Myositis/myopathy* 6 (14%) 1 (2.56%) - 
      NS – Not Seen in the study,             * not defined in ACR nomenclature  
 
 
Some of the defined NPSLE syndromes like demyelinating disease, 
aseptic meningitis, myelopathy, anxiety disorder, autonomic disorder, 
myasthenia, cranial neuropathy and plexopathy were not seen in the present 
study. 
 
The presence of past or current psychiatric diagnoses based on DSM-IV 
criteria  is also common in the present cohort, although past or current psychosis 
is rare. The frequency of individual psychiatric manifestations is comparable to 
that previously reported.6,7,8 
The main weakness of the study is the small sample size, and therefore 
the results should to be interpreted with caution. As a cross-sectional study, the 
validity of disease history depends on the documentation of past disease 
episodes. Though this is unlikely to have a substantial effect on the prevalence 
rates of the NP syndromes, reliable discrimination between primary NPSLE, 
secondary NPSLE, and concurrent disease process becomes problematic. It has 
been estimated that two-thirds of NP manifestations in SLE are not directly 
related to NPSLE but are due to secondary causes such as drugs, infections, and 
metabolic complications of the disease.52,53 Prospective analyses would help in 
discriminating between primary and secondary NPSLE. 
 
 
 
 
 
 
CONCLUSIONS 
 
1. Atleast one Neuropsychiatric SLE (NPSLE) syndrome was found in 70% 
of SLE patients admitted. 
2. Females were more predominant (F:M=20:1) 
3. 9.5% of patients presented with NPSLE as the first manifestation of SLE.  
4. Headache was the most common presentation seen in 54.7% patients 
followed by mood disorders(depression) (47.6%). Migraine without aura 
was the most common type of headache noted. 
5. Psychosis was seen only in 12% of patients. 
6. Peripheral nerve disorders were seen in 12% of the patients. 
7. Seizure disorder was seen in 33% of patients, generalized seizure being 
the most common among them. 
8. Tremor disorder seen in 4.8% of the patients. 
9. Some of the defined NPSLE syndromes like demyelinating diseases, 
aseptic meningitis, myelopathy, anxiety disorder, autonomic disorder, 
myasthenia, cranial neuropathy and plexopathy were not observed in the 
present study. 
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ANNEXURE 1 
Case Definitions for Neuropsychiatric Syndromes in Systemic Lupus 
Erythematosus 
(ACR Ad Hoc committee on neuropsychiatric lupus nomenclature: The American College of 
Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. 
Arthritis Rheum 1999;42:599–608, and from John Wiley and Sons.) 
 
1. Acute confusional state  
Disturbance of consciousness or level of arousal characterized by reduced ability to focus, maintain, 
or shift attention, and accompanied by disturbances of cognition, mood, affect, and/or behavior. The 
disturbances typically develop over hours to days and tend to fluctuate during the course of the day. 
They include hypo- and hyperaroused states and encompass the spectrum from delirium to coma. 
Diagnostic criteria: 
Disturbance of consciousness or level of arousal with reduced ability to focus, maintain, or shift 
attention, and one or more of the following developing over a short period of time (hours to days) and 
tending to fluctuate during the course of the day: 
a. Acute or subacute change in cognition that may include memory deficit and disorientation. 
b. A change in behavior, mood, or affect (e.g., restlessness, overactivity, reversal of the 
sleep/wakefulness cycle, irritability, apathy, anxiety, mood lability, etc.). 
Exclusions: 
• Primary mental/neurological disorder not related to systemic lupus erythematosus (SLE). 
• Metabolic disturbances (including glucose, electrolytes, fluid, osmolarity). 
• Substance or drug-induced delirium (including withdrawal). 
• Cerebral infections. 
Associations: 
• Marked psychosocial stress. 
• Corticosteroid use. 
• Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. 
 
2. Acute inflammatory demyelinating polyradiculoneuropathy  
Diagnostic criteria: 
a. Clinical features 
i. Progressive polyradiculoneuropathy, usually ascending and predominantly motor, which peaks 
usually within 21 days or less. 
ii. Reflex loss. 
iii. Symmetric, may involve the trunk and may cause respiratory failure. 
b. Cerebrospinal fluid(CSF) 
i. Increased CSF protein without pleocytosis. 
c. Supportive evidence by nerve conduction study including F-wave ascertainment whereby there is 
one abnormality in three nerves.The abnormalities are: 
i. Conduction block in which the amplitude of compound muscle action potential diminishes with 
more proximal sites of nerve stimulation. 
ii. F waves may be absent or prolonged. 
iii. Slowing of conduction velocity. 
iv. Prolongation of distal latencies. 
Exclusions: 
• Acute spinal cord disease. 
• Botulism. 
• Poliomyelitis and other infections. 
• Acute myasthenia gravis. 
 
3. Anxiety disorder 
Anticipation of danger or misfortune accompanied by apprehension, dysphoria, or tension. Includes 
generalized anxiety, panic disorder, panic attacks, and obsessive-compulsive disorders. 
Diagnostic criteria: 
Both of the following: 
a. Prominent anxiety, panic disorder, panic attacks, or obsessions or compulsions. 
b. Disturbance causes clinically significant distress or impaired social, occupational, or other 
important functioning. 
Exclusions: 
• Adjustment disorder with anxiety (e.g., maladaptive response to stress of having SLE). 
• Substance- or drug-induced anxiety. 
• Anxiety occurring exclusively during the course of an acute confusional state, a mood disorder, or 
psychosis. 
Associations: 
• Metabolic disorders, e.g., hyperthyroidism, pheochromocytoma. 
• Marked psychosocial stress. 
• Corticosteroid use. 
 
4. Aseptic Meningitis 
Diagnostic criteria: 
All the following: 
a. Acute or subacute onset of headache with photophobia, neck stiffness, and fever. 
b. Signs of meningeal irritation. 
c. Abnormal CSF. 
Exclusions: 
Central nervous system (CNS) or meningeal inflammation because of: 
a. Infection by bacteria, mycobacteria, viruses, fungi, parasites. 
b. Subarachnoid hemorrhage. 
c. Malignancy (leukemia, lymphoma, or carcinoma) or granulomatous disease (sarcoidosis). 
d. Medications: nonsteroidal anti-inflammatory drugs, intravenous immunoglobulin, azathioprine, etc. 
 
5. Autonomic disorder 
Disorder of the autonomic nervous system with orthostatic hypotension, sphincteric 
erectile/ejaculatory dysfunction, anhidrosis, heat intolerance, constipation. 
Diagnostic criteria: 
Symptoms and abnormal response to provocative tests: 
Test normal range 
a. Blood pressure response to standing: fall in blood pressure more than 30/15 mmHg or vertical tilt 
(systolic/diastolic). 
b. Heart rate response to standing: increases 11–29 beats/minute. 
c. Heart rate variation with respiration: maximum–minimum heart rate: 15 beats/minute; E:I ratio 
(ratio of heart rate during expiration and inspiration): 1:2. 
c. Valsalva ratio: 1:4. 
d. Sweat test: Sweating over all body and limbs. 
Exclusions: 
• Autonomic dysfunction with Lambert-Eaton syndrome. 
• Medications: tricyclic antidepressants. 
• Poisons: organophosphates. 
• Shy-Drager syndrome. 
Associations: 
• Diabetic neuropathy and peripheral neuropathy of other causes. 
• Autonomic failure in elderly. 
 
6. Cerebrovascular disease  
Diagnostic criteria: 
One of the following and supporting radioimaging study: 
a. Stroke syndrome: acute focal neurological deficit persisting more than 24 hours (or lasting less than 
24 hours with computed tomography (CT) or magnetic resonance imaging (MRI) abnormality 
consistent with physical findings/symptoms. 
b. Transient ischemic attack: acute, focal neurological deficit with clinical resolution within 24 hours 
(without corresponding lesion on CT or MRI). 
c. Chronic multifocal disease: recurrent or progressive neurological deterioration attributable to 
cerebrovascular disease. 
d. Subarachnoid and intracranial hemorrhage: bleeding documented by CSF findings, MRI/CT. 
e. Sinus thrombosis: Acute, focal neurological deficit in the presence of increased intracranial 
pressure. 
Note: The finding of unidentified bright objects on MRI without clinical manifestations is not 
classified at the present time. 
Exclusions: 
• Infection with space occupying lesions in the brain. 
• Intracranial tumor. 
• Trauma. 
• Vascular malformation. 
• Hypoglycemia. 
Associations: 
• Diabetes mellitus. 
• Dyslipidemia. 
• Atherosclerotic vascular disease. 
• Atrial fibrillation. 
• Valvular heart disease. 
• Atrial septal defect. 
• Hypercoagulability state. 
• Antiphospholipid antibody syndrome. 
• Hypertension. 
• Smoking. 
• Cocaine or amphetamine abuse. 
 
7. Cognitive Dysfunction 
Significant deficits in any or all of the following cognitive functions: simple or complex attention, 
reasoning, executive skills (e.g., planning, organizing, sequencing), memory (e.g., learning and 
recall), visuospatial processing, language (e.g., verbal fluency), and psychomotor speed. Cognitive 
dysfunction  implies a decline from a higher level of functioning and ranges from mild impairment to 
severe dementia. It may or may not impede social, educational, or occupational functioning, 
depending on the function(s) impaired and the severity of impairment. Subjective complaints of 
cognitive dysfunction are common and may not be objectively verifiable. Neuropsychological testing 
should be done in suspected cognitive dysfunction, and its interpretation should be done with a 
neuropsychologist. 
Diagnostic criteria: 
a. Documented impairment in one or more of the following cognitive domains: 
i. Simple attention. 
ii. Complex attention. 
iii. Memory (e.g., learning and recall). 
iv. Visuospatial processing. 
v. Language (e.g., verbal fluency). 
vi. Reasoning/problem solving. 
vii. Psychomotor speed. 
viii. Executive functions (e.g., planning, organizing, and sequencing). 
b. The cognitive deficits represent a significant decline from a former level of functioning (if known). 
c. The cognitive deficits may cause varying degrees of impairment in social, educational, or 
occupational functioning, depending on the function(s) impaired and the degree of impairment. 
Associations: 
• Substance abuse. 
• Medication (steroids, sedatives). 
• History of learning disabilities. 
• History of head injury. 
• Other primary neurological and psychiatric disorders. 
• Metabolic disturbances, particularly uremia and diabetes. 
• Antiphospholipid antibody syndrome. 
• Coexisting emotional distress, fatigue, and pain. 
 
8. Demyelinating syndrome  
Diagnostic criteria: 
Two or more of the following, each occurring at different times, or one of the following occurring on 
at least two different occasions: 
a. Multiple discrete areas of damage to white matter within CNS, causing one or more limbs to 
become weak with sensory loss. 
b. Transverse myelopathy. 
c. Optic neuropathy. 
d. Diplopia because of isolated nerve palsies or internuclear ophthalmoplegia. 
e. Brain stem disease with vertigo, vomiting, ataxia, dysarthria, or dysphagia. 
f. Other cranial nerve palsies. 
Exclusions: 
• Infections, e.g., tuberculosis, human T-cell lymphotropic virus-I, HIV, cytomegalovirus, Borrelia, 
CNS Whipple’s disease, progressive multifocal leukoencephalopathy, syphilis. 
• Vitamin B12 deficiency. 
Associations: 
• Structural lesions, e.g., tumor, arteriovenous malformation. 
• Familial disorders, e.g., hereditary spastic paraplegia, ataxia, and leukodystrophies. 
• Sarcoid, Behçet’s disease, other vasculitis. 
• Multiple sclerosis. 
 
9. Headache 
a. Migraine 
i. Migraine without aura: Idiopathic, recurrent headache manifested by attacks lasting 4–72 hours. 
Typical characteristics are unilateral location, pulsating quality, moderate-to-severe intensity, 
aggravation by routine physical activity, and associated with nausea, vomiting, photo- and 
phonophobia. At least five attacks fulfilling the aforementioned criteria. 
ii. Migraine with aura: Idiopathic, recurrent disorder manifested by attacks of neurological symptoms 
localizable to cerebral cortex or brain stem, usually gradually developing over 5–20 minutes and 
lasting less than 60 minutes. Headache, nausea, and/or photophobia usually follow neurologic aura 
symptoms directly or after an interval of less than 1 hour. Headache usually 
lasts 4–72 hours, but may be completely absent. 
b. Tension headache (episodic tension-type headache). 
Recurrent episodes of headaches lasting minutes to days. Pain typically pressing/tightening in quality, 
of mild-to-moderate intensity, bilateral in location, and does not worsen with routine physical 
activity. Nausea is rare, but photophobia and phonophobia may be present. At least 10 previous 
headaches fulfilling these criteria 
c. Cluster headache. 
Attacks of severe, strictly unilateral pain, orbital, supraorbital, and/or temporal, usually lasting 15–
180 minutes and occurring from at least once every other day up to eight times per day. Associated 
with one or more of the following: conjunctival injection, lacrimation, nasal congestion, rhinorrhea, 
forehead and facial sweating, miosis, ptosis, eyelid edema. Attacks occur in series for weeks or 
months (“cluster” periods), separated by remissions of usually months or years. 
d. Headache from intracranial hypertension (also called pseudotumor cerebri, benign intracranial 
hypertension) 
All of the following: 
i. Increased intracranial pressure (200 mm H2O) measured by lumbar puncture. 
ii. Normal neurological findings, except for papilledema and possible nerve VI palsy. 
iii. No mass lesion and no ventricular enlargement on neuroimaging. 
iv. Normal or low protein and normal white cell count in CSF. 
v. No evidence of venous sinus thrombosis. 
e. Intractable headache, nonspecific. 
Exclusions: 
• Aseptic meningitis (including drug-induced). 
• Drug-induced pseudotumor cerebri (oral contraceptives, sulfonamides, trimethoprim, etc.). 
• CNS infection. 
• Tumors and other structural lesions. 
• Low intracranial pressure. 
• Trauma. 
• Metabolic headache that remits with elimination of cause (carbon monoxide exposure). 
• Withdrawal (caffeine, etc.). 
• Seizure/postictal state. 
• Sepsis. 
• Intracranial hemorrhage or vascular occlusion. 
 
10. Mononeuropathy (single/multiplex) 
Disturbed function of one or more peripheral nerve(s) resulting in weakness/paralysis or sensory 
dysfunction because of either conduction block in motor nerve fibers or axonal loss. Conduction 
block is related to demyelination with preservation of axon continuity. Remyelination may be rapid 
and complete. If axonal interruption takes place, axonal degeneration occurs below the site of 
interruption and recovery is often slow and incomplete. Sensory symptoms and sensory loss may 
affect all modalities or be restricted to certain forms of sensation. 
Diagnostic criteria: 
a. Clinical demonstration of motor/sensory disturbances in the distribution of a peripheral nerve 
and/or 
b. Abnormalities on nerve conduction studies or electromyogram (EMG) (i.e., concentric needle 
examination). 
Associations: 
• Diabetic neuropathy. 
• Local damage from mechanical injury, radiation, malignancy, sarcoid. 
• Infection: Lyme disease, HIV, herpes. 
• Vasculitis, polyarteritis nodosa, Wegener’s granulomatosis, cryoglobulinemia, rheumatoid arthritis, 
Sjögren’s syndrome, etc. 
 
 
11. Mood disorders 
Prominent and persistent disturbance in mood characterized by: 
• Depressed mood or markedly diminished interest or pleasure in almost all activities or 
• Elevated, expansive or irritable mood. 
Diagnostic criteria: 
a. Major depressive-like episode. 
One or more major depressive episodes with at least five of the following symptoms, including either 
i or ii or both, during a 2-week period and nearly every day: 
i. Depressed mood most of the day, by subjective report or observation made by others. 
ii. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, by 
subjective report or observation made by others. 
iii. 
(1) Significant weight loss without dieting or weight gain (>5% of body weight in 1 month). 
(2) Insomnia or hypersomnia. Psychomotor agitation or retardation (observable by others, not merely 
subjective feeling of restlessness or being slowed down). 
(3) Fatigue or loss of energy. 
(4) Feelings of worthlessness or excessive or inappropriate guilt (may be delusional). 
(5) Diminished ability to think or concentrate, or indecisiveness. 
(6) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific 
plan, or a suicide attempt or a specific plan for committing suicide. 
b. Mood disorder with depressive features. 
All of the following: 
i. Prominent and persistent mood disturbance characterized by predominantly depressed mood or 
markedly diminished interest or pleasure in all, or almost all, activities. 
ii. Full criteria for major depressive-like episode are not met. 
c. Mood disorder with manic features. 
i. Prominent and persistent mood disturbance characterized by predominantly elevated, expansive, or 
irritable mood. 
e. Mood disorder with mixed features. 
i. Prominent and persistent mood disturbance characterized by symptoms of both depression and 
mania; neither predominates. 
For all mood disorders: 
Symptoms must cause significant distress or impairment in social, occupational, or other important 
areas of functioning. 
Exclusions: 
• Primary mental disorders. 
• Substance-induced mood disorder. 
• Adjustment disorder with depressed mood. 
 
12. Movement disorder (chorea) 
Chorea: Irregular, involuntary brief and unpredictable, jerky movements that may involve any portion 
of the body in random sequence. 
Diagnostic criteria: 
Both of the following: 
a. Observed abnormal movements. 
b. Random, unpredictable sequence of movements. 
Exclusions: 
• Wilson’s disease. 
• Huntington’s disease (and other hereditary disorders). 
• Medications (neuroleptics, oral contraceptives, phenytoin, L-DOPA, calcium channel blockers). 
• Illicit drugs. 
13. Myasthenia gravis  
Neuromuscular transmission disorder characterized by fluctuating weakness and fatigability of bulbar 
and other voluntary muscles without loss of reflexes or impairment of sensation or other neurological 
function. Myasthenia gravis is an autoimmune disorder mediated by antibodies to acetylcholine 
receptors. It may occur with other diseases of immunological origin. 
Diagnostic criteria: 
a. Characteristic signs and symptoms include one or more of the following: 
i. Diplopia, ptosis, dysarthria, weakness in chewing, difficulty in swallowing, muscle weakness with 
preserved deep tendon reflexes, and, less commonly, weakness of neck extension and flexion, and 
weakness of trunk muscles. 
ii. Increased weakness during exercise and repetitive use with at least partially restored strength after 
periods of rest. 
iii. Dramatic improvement in strength following administration of anticholinesterase drug 
(edrophonium and neostigmine). 
And one or more of the following: 
b. EMG and repetitive stimulation of a peripheral nerve: In myasthenia gravis, repetitive stimulation 
at a rate of two per second shows characteristic decremental response that is reversed by edrophonium 
or neostigmine. Single-fiber studies show increased jitter. 
c. Antibodies to acetylcholine receptors. 
Exclusions: 
• Congenital myasthenic syndrome, progressive restricted myopathies, steroid and inflammatory 
myopathies, motor neuron disease. 
• Multiple sclerosis, variants of Guillain-Barre syndrome (e.g., Miller-Fisher syndrome). 
• Organophosphate toxicity, botulism, black widow spider venom. 
• Eaton-Lambert syndrome. 
• Stroke. 
• Medications: neuromuscular blocking agents, aminoglycosides, penicillamine, antimalarial drugs, 
colistin, streptomycin, polymyxin B, tetracycline. 
• Hypokalemia; hypophosphatemia. 
Associations: 
• Pure red cell aplasia. 
• Thyroid abnormalities. 
• Thymoma. 
 
14. Myelopathy  
Diagnostic criteria: 
Usually rapid onset (hours or days) of one or more of the following: 
a. Bilateral weakness of legs with or without arms (paraplegia/quadriplegia); may be asymmetric. 
b. Sensory impairment with cord level similar to that of motor weakness, with or without bowel and 
bladder dysfunction. 
Exclusions: 
• Mass lesion causing compression of or within spinal cord (e.g., prolapsed disc, tumor, hematoma, or 
ruptured spinal arteriovenous malformation). 
• Cauda equina lesion. 
 
15. Neuropathy, cranial 
Diagnostic criteria: 
Syndrome corresponding to specific nerve function: 
a. Olfactory nerve: loss of sense of smell, distortion of smell, and loss of olfactory discrimination. 
b. Optic nerve: decrease or loss of visual acuity, diminished color perception, afferent pupillary 
defect, and visual field deficits. 
c. Oculomotor nerve: ptosis of the upper eyelid and inability to rotate eye upward, downward, or 
inward (complete lesion), and/or dilated nonreactive pupil and paralysis of accommodation 
(interruption of parasympathetic fibers only). 
d. Trochlear nerve: extorsion and weakness of downward movement of affected eye. 
e. Abducens nerve: weakness of eye abduction. 
f. Trigeminal nerve: paroxysm of pain in lips, gums, cheek, or chin initiated by stimuli in trigger zone 
(trigeminal neuralgia) and sensory loss of the face or weakness of jaw muscles. 
g. Facial nerve: unilateral or bilateral paralysis of facial expression muscles, or impairment of taste, or 
hyperacusis (painful sensitivity to sounds). 
h. Vestibulo-cochlear nerve: deafness, tinnitus (cochlear), dizziness, and/or vertigo (vestibular). 
i. Glossopharyngeal nerve: swallowing difficulty, deviation of soft palate to normal side, anesthesia 
of posterior pharynx and/or glossopharyngeal neuralgia (unilateral stabbing pain in root of tongue and 
throat, triggered by coughing, sneezing, swallowing, and pressure on ear tragus). 
j. Vagus nerve: soft palate droop, loss of the gag reflex, hoarseness, nasal voice, and/or loss of 
sensation at external auditory meatus. 
k. Accessory nerve: weakness and atrophy of sternocleidomastoid muscle and upper part of trapezius 
muscle. 
l. Hypoglossal nerve: paralysis of one side of tongue with deviation to the affected side. 
Exclusions: 
• Skull fracture. 
• Tumor: meningioma, carcinomatous meningitis, aneurysm. 
• Infection: herpes zoster, neuroborreliosis, syphilis, mucormycosis. 
• Miller-Fisher syndrome. 
 
16. Plexopathy 
Disorder of brachial or lumbosacral plexus producing muscle weakness, sensory deficit, and/or reflex 
change not corresponding to the territory of single root or nerve. 
Diagnostic criteria: 
All of the following: 
a. Characteristic signs and symptoms: 
i. Brachial plexus: deep pain in shoulder, muscle weakness, sensory deficit and/or reflex impairment 
of arm, or 
ii. Lumbosacral plexus: deep boring pain in thigh, muscle weakness, sensory deficit, and/or reflex 
impairment of leg. 
b. Positive EMG finding (concentric needle examination) and/or nerve conduction studies for EMG: 
more than one root or nerve abnormalities with sparing of paraspinal muscles for nerve conduction 
study: absent or reduced amplitude on motor or sensory nerve conduction. 
c. Normal MRI or CT scan (optional: myelogram) to rule out a higher neurological lesion. 
Exclusions: 
• Damage from injury, compression, tumor, aneurysm, radiation. 
• Cervical rib, thoracic outlet syndrome. 
• Plexus neuritis. 
• Toxic: heroin. 
• Infectious: Lyme disease, leprosy, herpes zoster. 
 
17. Polyneuropathy 
Acute or chronic disorder of sensory and motor peripheral nerves with variable tempo characterized 
by symmetry of symptoms and physical findings in a distal distribution. 
Diagnostic criteria: 
One or both of the following: 
a. Clinical manifestations: 
i. Clinical demonstration of distal sensory and/or motor deficit. 
ii. Symmetry of signs/symptoms, and/or. 
b. Confirmation by EMG: 
i. Concentric needle examination demonstrating denervation of muscle, or 
ii. Nerve conduction study demonstrating axonal or demyelinating neuropathy. 
Exclusions: 
• Vitamin deficiencies: B12, niacin, thiamine. 
• Hypothyroidism. 
 
18. Psychosis 
Severe disturbance in the perception of reality characterized by delusions and/or hallucinations 
Diagnostic criteria: 
All of the following: 
a. At least one of the following: 
i. Delusions. 
ii. Hallucinations without insight. 
b. The disturbance causes clinical distress or impairment in social, occupational, or other relevant 
areas of functioning. 
c. The disturbance does not occur exclusively during the course of a delirium. 
d. The disturbance is not better accounted for by another mental disorder (e.g., mania). 
Exclusions: 
• Primary psychotic disorder unrelated to SLE (e.g., schizophrenia). 
• Substance- or drug-induced psychotic disorder (including nonsteriodal anti-inflammatory drugs, 
antimalarials). 
• Psychologically mediated reaction to SLE (brief reactive psychosis with major stressor). 
 
19. Seizures and seizure disorders 
Abnormal paroxysmal neuronal discharge in the brain causing abnormal function. Isolated seizures 
are distinguished from the diagnosis of epilepsy. Epilepsy is a chronic disorder characterized by an 
abnormal tendency for recurrent, unprovoked seizures that are usually stereotypic. Approximately 3% 
of the population has epilepsy. Typically, provoked seizures result from treatable conditions, such as 
sleep deprivation, toxic exposure to stimulants, withdrawal from narcotics, barbiturates, or alcohol, 
fever, 
infection, metabolic disturbances, or SLE. 
The approach to the evaluation of patients with a new-onset spell that may be a seizure, and the 
classification of seizures regardless of whether they are isolated seizures or part of a seizure disorder 
(e.g., epilepsy), are the same. The approach to treatment, however, is usually different. Although 
anticonvulsants are effective in controlling seizures acutely whether provoked or not, continuous 
prophylaxis is principally reserved for patients with epilepsy. Seizures may occur with or without the 
loss of consciousness. Seizures are divided into partial and generalized. Partial seizures have clinical 
or electroencephalographic evidence of a focal onset; the abnormal discharge usually arises in a 
portion of one hemisphere and may spread to the rest of the brain during a seizure. Primary 
generalized seizures have no interictal evidence of focal onset on electroencephalogram (EEG). A 
generalized seizure can be primary or secondary. 
a. Primary generalized seizures (bilaterally symmetric and without local onset). 
i. Tonic clonic (grand mal) or tonic or clonic. 
ii. Atonic or astatic seizures. 
iii. Absence seizures (petit mal). 
Typical absences consist of abrupt onset and cessation of impairment of consciousness, with or 
without automatism, myoclonic jerks, tonic or autonomic components. A 3-Hz spike and wave 
discharge is usual EEG abnormality. Atypical absences have less abrupt onset and/or cessation of 
impaired consciousness and are more prolonged in tone with EEG abnormalities other than 3-Hz 
spike and wave discharge. 
iv. Myoclonic seizures. 
b. Partial or focal seizures (seizures beginning locally) (also referred to as Jacksonian, temporal lobe, 
or psychomotor seizure, according to type). 
i. Simple, without impairment of consciousness. Depending on anatomic site of origin of seizure 
discharge, initial symptom may be motor, sensory, aphasic, cognitive, affective, dysmnesic, illusional, 
olfactory, or psychological.. 
ii. Complex, with partial impairment of consciousness, which may be simple at onset, followed by 
alteration or impairment of consciousness. Symptoms same as in i. 
iii. Simple or complex may evolve to secondary generalized tonic/clonic seizures. Sometimes 
secondary generalization is so rapid that there is no clinical evidence of partial onset, only 
electroencephalographic. 
Diagnostic criteria: 
a. Independent description by a reliable witness. 
b. EEG abnormalities. 
Exclusions: 
Seizure-like signs or symptoms or seizure from 
• Vasovagal syncope. 
• Cardiac syncope. 
• Hysteria. 
• Hyperventilation. 
• Tics. 
• Narcolepsy and cataplexy. 
• Labyrinthitis. 
• Alcohol and drug withdrawal. 
• Medications: quinolones, imipenem. 
• Subarachnoid hemorrhage. 
• Trauma. 
• Hypoglycemia. 
• Panic attacks, conversion disorders, and malingering. 
 
 
 
 
 
 
 
A study on ‘NEUROPSYCHIATRIC MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS’ 
 
 
PROFORMA 
 
Name:    Age/Sex:  OP/IP No: 
       Date: 
Address:      Phone No: 
 
Complaints (Neurological) 
Headache    :  □    
Involuntary movements    : □  
Seizures    : □ 
Altered sensorium   : □ 
Weakness             : □  
Muscle pain   :         □ 
Numbness/parasthesias  : □  
Cranial nerve symptoms  : □ 
Postural hypotension  : □ 
Hallucinations/delusions  :  □ 
Others    :  □ 
 
 
 
 
 
 
 
Complaints (Non-Neurological) 
Joint pains  □   Rashes   □ 
Oral ulcers  □   Renal symptoms □ 
Chest pain/dyspnoea/palpitation □   others  □ 
 
 
 
 
 
      
No.   
 
ACR  CRITERIA: 
1. Malar rash .  
2. Discoid rash  
3. Photosensitivity  
4. Oral ulcers  
5. Arthritis  
6. Serositis   
a. Pleuritis  OR   
b.  Pericarditis 
7. Renal disorder  
8. Neurological disorder a. Seizures 
9. Hematological disorder  
10. Immunological disorder    
a.  Positive LE cell preparation OR 
b.  Anti‐DNA: OR  
c.  Anti‐Sm: OR  
11. Antinuclear antibody 
 
 
Laboratory Investigations: 
Hb:      TC:        DC: P‐       L‐      E‐ 
ESR:      mm/hr 
 
 
Blood urea:      mg/dl      Serum creatinine:    mg/dl 
 
Anti Nuclear Antibody: 
 
dsDNA antibody: 
 
Anti cardiolipin antibody: 
 
Lupus Anticoagulant: 
 
 
Imaging:  
 
CT Brain: 
 
MRI Brain: 
 
MRI spinal cord: 
 
CSF analysis: 
 
 
Others: 
 
 
 
 
 
Nerve Conduction Studies: 
 
MOTOR NERVE CONDUCTION STUDY 
NERVE 
LATENCY 
milli sec 
AMPLITUDE 
mV NCV 
 
m/s 
F wave 
 
milli sec Distal Proximal Distal Proximal 
Right Median             
Right Ulnar             
Left Median             
Left Ulnar             
Right Tibial             
Right Peroneal             
Left Tibial             
Left Peroneal             
SENSORY NERVE CONDUCTION STUDY 
NERVE LATENCY AMPLITUDE VELOCITY 
Right Median   
Right Ulnar   
Left Median   
Left Ulnar   
Right Sural   
Left Sural 
 
 
 
ELECTROMYOGRAPHY(EMG): 
 
 
ELECTROENCEPHALOGRAPHY(EEG): 
 
NEUROPSYCHIATRIC : ACR NOMENCLATURE 
1. Acute confusional state 
2. Acute inflammatory demyelinating polyradiculoneuropathy 
3. Anxiety disorder 
4. Aseptic Meningitis 
5. Autonomic disorder 
6. Cerebrovascular disease 
7. Cognitive Dysfunction 
8. Demyelinating syndrome 
9. Headache 
10. Mononeuropathy (single/multiplex) 
11. Mood disorders 
12. Movement disorder 
13. Myasthenia gravis 
14. Myelopathy 
15. Neuropathy, cranial 
16. Plexopathy 
17. Polyneuropathy 
18. Psychosis 
19. Seizures and seizure disorders 
 
 
TREATMENT 
 
Drugs given: 
 
Duration of hospital stay: 
 
19 CHRISTINA 4 11 29 Y Y Right 
20 REVATHI 4 29 26 Y Y norm
21 SAMSHAD BEGUM 6 26 30 Y Y Axona
22 SASI 4 7 29 Y norm
23 PARVATHI 4 3 12 Y norm
24 JASMINE 5 32 30 Y Y Y Y norm
25 VALLI 4 5 30 Y norm
26 NANDHINI 4 11 30 Y norm
27 SAKTHI 4 19 0 Y Y Y Y Y Y norm
28 PAULRAJ 4 9 29 Y Monon
29 BRINDHA 4 5 27 Y AIDP
30 PRIYA 4 40 28 Y Y Y norm
31 SHALINI 5 7 30 Y norm
32 SARASWATHY 4 3 30 norm
33 SUNDARI 5 5 30 Y norm
34 BHARATHI 7 29 27 Y Y Y norm
35 PRITHIMA  4 30 20 Y norm
36 BARGHAVI 4 9 16 Y norm
37 SOPHIA 4 21 12 Y Y Y norm
38 HAMSAVENI 4 4 11 Y norm
39 KANCHANA 4 2 20 Y norm
40 VIJAYALAKSHMI 5 22 30 Y Y Y norm
41 INDIRA 4 29 30 Y Y norm
42 ISHTIAQ 4 11 29 Y norm
